• Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts
  

• Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.

BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it will be attending the Annual Sidoti Micro-Cap Virtual Conference being held on August 16-17, 2023.

“We’ve made a lot of progress since we’ve announced the strategic reprioritization of our drug pipeline making this an opportune time to share updates with the investment community,” says Randy Milby, CEO of Hillstream. “Sidoti has fostered a strong tight knit group of movers and shakers within the micro-cap world, and we believe this group will be a good fit for understanding our true value proposition as we continue to make advancements with our HER2/HER3 program and transform Hillstream into a focused and targeted cancer biologics company.”

The Company recently announced its expansion of collaboration with Minotaur Therapeutics, Inc. and of its license agreement with OmniAb, Inc. to propel the advancement of next generation targeted Knob biologics (Picobodies™) development against HER3 and a new undisclosed oncology target. This will in turn complement Hillstream’s HSB-3215 program.

To schedule a meeting with the management team or view the presentation, please send an email to investorrelations@hillstreambio.com or visit https://www.meetmax.com/sched/event_96493/investor_reg_new.html?attendee_role_id=SIDOTI_INVESTOR.

About Hillstream BioPharma Inc.
Hillstream BioPharma, Inc. is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug resistant and devastating cancers. The Company’s emerging immuno-oncology pipeline is led by HSB-3215, a novel anti-HER2/HER3 monoclonal antibody targeting unique epitopes with a novel mechanism of action. The erbB/HER family of cell surface proteins include well-known and validated drug targets including HER2 and HER3 found in multiple solid tumors, including breast, lung, GYN, endocrinological and CNS. Hillstream has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against specified targets. For more information, please visit: www.hillstreambio.com.